Aromatose Inhibitor

Questions discussed in this category

What is the preferred duration of adjuvant aromatase inhibitor therapy in patients with triple positive breast cancer?

Does node positivity affect your decision? Is there a role for predictive/prognostic test?

1 Answer available

Papers discussed in this category

Journal of the National Cancer Institute, 2005-09-07

Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.

J. Natl. Cancer Inst.,

Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05).

Cancer chemotherapy and pharmacology, 2009 Dec 03

Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2022 May 02

Breast Cancer Index Is a Predictive Biomarker of Treatment Benefit and Outcome from Extended Tamoxifen Therapy: Final Analysis of the Trans-aTTom Study.

Acta oncologica (Stockholm, Sweden), 2007

Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2024 May 01

Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial.

Related Topics